168 related articles for article (PubMed ID: 32009825)
1. Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study.
Simpson ML; Kulkarni R; Escuriola Ettingshausen C; Medom Meldgaard R; Cooper DL; Klamroth R
J Blood Med; 2019; 10():391-398. PubMed ID: 32009825
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
[TBL] [Abstract][Full Text] [Related]
3. Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial.
Escuriola Ettingshausen C; Hegemann I; Simpson ML; Cuker A; Kulkarni R; Pruthi RK; Garly ML; Meldgaard RM; Persson P; Klamroth R
Res Pract Thromb Haemost; 2019 Apr; 3(2):268-276. PubMed ID: 31011711
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials.
Mancuso ME; Eriksson D; Falk A; Hakimi Z; Wojciechowski P; Wdowiak M; Klamroth R
J Blood Med; 2023; 14():427-434. PubMed ID: 37534261
[TBL] [Abstract][Full Text] [Related]
5. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
[TBL] [Abstract][Full Text] [Related]
6. Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real-world, multicenter, retrospective study.
Matino D; Iorio A; Keepanasseril A; Germini F; Caillaud A; Carcao M; Hews-Girard J; Iserman E; James P; Lee A; Phua CW; Sun HL; Teitel J; Poon MC
Res Pract Thromb Haemost; 2022 Mar; 6(3):e12661. PubMed ID: 35386274
[TBL] [Abstract][Full Text] [Related]
7. Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes.
Iorio A; MacDonald V; Caillaud A; Luckevich MD; Christoffersen P; Matino D; Keepanasseril A; Iserman E; Germini F; Bentley A; Poon MC
Res Pract Thromb Haemost; 2023 Mar; 7(3):100106. PubMed ID: 37065846
[TBL] [Abstract][Full Text] [Related]
8. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
Tiede A; Abdul-Karim F; Carcao M; Persson P; Clausen WHO; Kearney S; Matsushita T; Negrier C; Oldenburg J; Santagostino E; Young G
Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
[TBL] [Abstract][Full Text] [Related]
10. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
Oldenburg J; Carcao M; Lentz SR; Mahlangu J; Mancuso ME; Matsushita T; Négrier C; Clausen WHO; Ehrenforth S; Young G
Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
[TBL] [Abstract][Full Text] [Related]
11. Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.
Chan AK; Alamelu J; Barnes C; Chuansumrit A; Garly ML; Meldgaard RM; Young G
Res Pract Thromb Haemost; 2020 Oct; 4(7):1101-1113. PubMed ID: 33134776
[TBL] [Abstract][Full Text] [Related]
12. In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients.
Preijers T; van Spengler MWF; Meijer K; Fijnvandraat K; Fischer K; Leebeek FWG; Cnossen MH; Mathôt RAA
Eur J Clin Pharmacol; 2022 Feb; 78(2):237-249. PubMed ID: 34651201
[TBL] [Abstract][Full Text] [Related]
13. Performance of factor IX extended half-life product measurements in external quality control assessment programs.
Nederlof A; Kitchen S; Meijer P; Cnossen M; Ali Pour N; Kershaw G; Jennings I; Walker I; de Maat MPM
J Thromb Haemost; 2020 Aug; 18(8):1874-1883. PubMed ID: 32311825
[TBL] [Abstract][Full Text] [Related]
14. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice.
van der Flier A; Hong V; Liu Z; Piepenhagen P; Ulinski G; Dumont JA; Orcutt KD; Goel A; Peters R; Salas J
Blood Coagul Fibrinolysis; 2023 Sep; 34(6):353-363. PubMed ID: 37577860
[TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
O'Donovan M; Bergin C; Quinn E; Singleton E; Roche S; Benson J; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM
Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
[TBL] [Abstract][Full Text] [Related]
17. Nonacog beta pegol prophylaxis in children with hemophilia B: safety, efficacy, and neurodevelopmental outcomes for up to 8 years.
Walsh KS; Mrakotsky C; Carcao M; Chan AKC; Nielsen PH; Holst H; Shapiro K
Res Pract Thromb Haemost; 2024 Feb; 8(2):102341. PubMed ID: 38516633
[TBL] [Abstract][Full Text] [Related]
18. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.
Rosén P; Rosén S; Ezban M; Persson E
J Thromb Haemost; 2016 Jul; 14(7):1420-7. PubMed ID: 27169618
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B.
Carcao M; Kearney S; Lu MY; Taki M; Rubens D; Shen C; Santagostino E
Thromb Haemost; 2020 May; 120(5):737-746. PubMed ID: 32369845
[TBL] [Abstract][Full Text] [Related]
20. FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia
Ezban M; Hermit MB; Persson E
Haemophilia; 2019 Jan; 25(1):154-161. PubMed ID: 30664825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
